Lyra Therapeutics (LYRA) Operating Leases (2019 - 2025)
Lyra Therapeutics (LYRA) recorded quarterly Operating Leases of $25.4 million in Q4 2025, down 4.7% on a QoQ basis from $26.7 million in Q3 2025, and down 15.92% YoY from $30.3 million in Q4 2024.
Lyra Therapeutics (LYRA) Operating Leases (2019 - 2025) Analysis & Trends
Lyra Therapeutics (LYRA) has reported Operating Leases for 7 consecutive years, with $25.4 million the latest figure, recorded in Q4 2025.
- Operating Leases for Q4 2025 came in at $25.4 million, down 15.92% year-over-year; the trailing twelve-month figure through Dec 2025 was $25.4 million (down 15.92% YoY), and the FY2025 annual result was $25.4 million, down 15.92% from the prior year.
- Operating Leases for Q4 2025 stood at $25.4 million, down from $26.7 million in the prior quarter.
- The five-year high for Operating Leases was $33.4 million in Q1 2024, with the low at $3000.0 in Q2 2022.
- A 5-year average of $14.1 million and a median of $4.9 million in 2023 frame the typical range for Operating Leases.
- Across the five-year window, Operating Leases slumped 99.68% in 2022 and jumped 162800.0% in 2023, its largest moves.
- Lyra Therapeutics' Operating Leases stood at $379000.0 in 2021, then surged by 75.99% to $667000.0 in 2022, then surged by 3115.44% to $21.4 million in 2023, then soared by 41.09% to $30.3 million in 2024, then dropped by 15.92% to $25.4 million in 2025.
- The last three Operating Leases figures came in at $25.4 million (Q4 2025), $26.7 million (Q3 2025), and $27.9 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Lyra Therapeutics | 70,995.28 | 70,995.28 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 25.44 Mn |
| Sep 30, 2025 | 26.70 Mn |
| Jun 30, 2025 | 27.93 Mn |
| Mar 31, 2025 | 29.11 Mn |
| Dec 31, 2024 | 30.26 Mn |
| Sep 30, 2024 | 31.32 Mn |
| Jun 30, 2024 | 32.48 Mn |
| Mar 31, 2024 | 33.36 Mn |
| Dec 31, 2023 | 21.45 Mn |
| Sep 30, 2023 | 4.89 Mn |
| Mar 31, 2023 | 191,000.00 |
| Dec 31, 2022 | 667,000.00 |
| Sep 30, 2022 | 3,000.00 |
| Jun 30, 2022 | 3,000.00 |
| Mar 31, 2022 | 99,000.00 |
| Dec 31, 2021 | 379,000.00 |
| Sep 30, 2021 | 656,000.00 |
| Jun 30, 2021 | 929,000.00 |
| Mar 31, 2021 | 1.20 Mn |
| Dec 31, 2020 | 1.45 Mn |